Figure 5.
STK4 expression and 5-year survival of patients with EC. (A) STK4 protein expression shows a trend to decrease in Type 2 EC samples of deceased patients, i.e., in poorly differentiated cancers; bars in solid colors represent living individuals, bars with patterns—deceased patients; (B) as in (A), however, this phenomenon is better recognized in individuals with the Type 2 EC; (C) overall survival of patients with endometrioid (left two bars) and serous (right two bars) EC; high (above median) STK4 expression is associated with poor prognosis for patients with serous tumors (pink—% of living patients, blue—% of deceased patients).
